Charles River announces plans to acquire Vigene Biosciences

Laboratory services provider Charles River Laboratories, Inc. (MA, USA) is to acquire gene therapy contract development and manufacturing organization (CDMO) Vigene Biosciences (MD, USA). The acquisition will expand the cell and gene therapy CDMO capabilities of Charles River for viral vectors and plasmid DNA. Vigene Biosciences will bring expert knowledge and skills in cGMP viral vector manufacturing for utilization in gene therapies and gene-modified cell therapies. With significant expertise in adeno-associated virus cGMP  production, the acquisition will offer high-quality plasmid DNA for gene-modified cell therapies, gene therapies and vaccine production. You may also be interested in: Partnership announced to develop...